
News|Articles|February 13, 2019
Ultomiris for Paroxysmal Nocturnal Hemoglobinuria
Author(s)Drew Boxler
Advertisement
ULTOMIRIS (ravulizumab-cwvz , Alexion Pharmaceuticals, Inc.)
Indications: treatment of adult patients with paroxysmal nocturnal hemoglobinuria
Dosage: intravenous infusion only
- 40 kg ≤ X< 60 kg – 2,400mg leading, 3,000 mg maintenance
- 60kg ≤ X < 100kg – 2,700mg leading, 3,300mg maintenance
- 100kg ≤ X – 3,000mg leading, 3,600 maintenance
Contraindications: patients with unresolved Neisseria Meningitidis infection.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
How Pharmacists Take Control of Medical Billing
2
Data Show Rise in GLP-1 Poison Center Calls Tied to Dosing Errors
3
Lowered Pneumococcal Vaccination Age Has Yet to Close Awareness Gap
4
FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol
5






























